JNJ-64264681

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for JNJ-64264681, covering 2025-02-03 to 2025-08-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia [Phase 1]